Tripep's RAS technology and the German biotech company Cosmix' mRNA Display Technology will be co-developed in the new -

Tripep's RAS technology and the German biotech company Cosmix' mRNA Display
Technology will be co-developed in the new -

US company, Opsonics Therapeutics Inc.

Tripep and the German biotech company Cosmix AG have both licensed their
respective technologies (RAS and mRNA Display Library) to a newly formed US
company named Opsonic Therapeuticals Inc. within which Tripep's RAS technology
will be developed. The RAS technology is based on oligosaccharide linked
peptides that can redirect natural antibodies present in all humans to new
targets. Cosmix in turn has developed the mRNA Display Library technology by
which peptides that binds to a selected target rapidly are identified. Opsonic
will use Cosmix technology to identify target-binding peptides and these are
then used in RAS peptides aimed for therapeutic use. 

Cosmix AG has developed a mRNA Display Library by which ligand binding peptide
sequences are rapidly identified. Cosmix has license this technology to Opsonic
and in return obtained a 20% ownership. Likewise has Tripep licensed to Opsonic
an exclusive license to use the RAS technology development of new
pharmaceuticals. Tripep in return has also obtained a 20% ownership in Opsonic.
Among the founders of Cosmix are the inventors behind the two technologies Dr
Peter Wagner, Prof Matti Sällberg and Prof Anders Vahlne, and the CEO Albert
Collinson who has an extensive experience form leading positions in US and
European biotech.  

”This is a perfect marriage between two technologies that rapidly can generate
new peptide-based pharmaceuticals that use the unexplored pool of natural
antibodies in humans. This is a completely new and effective way to develop the
RAS technology into a commercial product”, says Opsonic's CEO Albert Collinson.


For more information, please contact:

Anders Vahlne, CEO & Head of Research, Tripep AB
Tel: +46 8 5858 1313, Mobile phone: +46 709 28 05 28
E-mail: anders.vahlne@ki.se


About Tripep
Tripep develops drugs against chronic disease based on proprietary and other
parties' patented and patent pending technologies. Tripep is focusing on the
following research projects; wound healing therapy ChronSeal® and a therapeutic
vaccine against Hepatitis C, named ChronVac-C®, plus the RAS® technology
platform. The Tripep share is admitted to trade on First North. Remium AB is
Certified Adviser for Tripep AB. For more information, please refer to the
company's website: www.tripep.se.

In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.